Replies to post #236099 on Biotech Values

[jbog]

Alxo has been a great performer. I'm too old to play the speculation game anymore but IOVA has had incredible gains recently with little to no news.

[biocqr]

Not ALXO...

ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock

https://www.globenewswire.com/news-release/2020/12/10/2142708/0/en/ALX-Oncology-Announces-Pricing-of-Upsized-Public-Offering-of-Common-Stock.html

BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the pricing of an upsized underwritten public offering of 2,380,000 shares of its common stock at a price of $76.00 per share.

[DewDiligence]

GILD acquires—(private)—MYR DmbH for $1.4B (€1.15B) plus contingencies:

https://www.businesswire.com/news/home/20201210005315/en/Gilead-Sciences-to-Acquire-MYR-GmbH

The acquisition will provide Gilead with Hepcludex (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020.

Chronic hepatitis D (a/k/a hepatitis delta) is a rare, but serious, complication of chronic HBV.

[biocqr]

Plieth's buyout...the "hot I/O target" is Ror1...

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

https://www.boehringer-ingelheim.com/press-release/agreement-acquire-nbe-therapeutics

About NBE-002
NBE-Therapeutics’ lead candidate, NBE-002, is an anti-ROR1 ADC. ROR1 is a receptor tyrosine kinase expressed in various hematologic and solid malignancies, including triple negative breast cancers and lung adenocarcinoma. The compound is currently in phase I clinical studies.